A detailed history of Aigen Investment Management, LP transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Aigen Investment Management, LP holds 9,817 shares of SRPT stock, worth $1.22 Million. This represents 0.31% of its overall portfolio holdings.

Number of Shares
9,817
Previous 1,711 473.76%
Holding current value
$1.22 Million
Previous $221,000 601.81%
% of portfolio
0.31%
Previous 0.05%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$113.33 - $163.85 $918,652 - $1.33 Million
8,106 Added 473.76%
9,817 $1.55 Million
Q1 2024

May 14, 2024

SELL
$93.7 - $141.53 $146,172 - $220,786
-1,560 Reduced 47.69%
1,711 $221,000
Q4 2023

Feb 09, 2024

BUY
$67.31 - $124.76 $220,171 - $408,089
3,271 New
3,271 $315,000
Q2 2023

Aug 14, 2023

SELL
$106.4 - $157.19 $896,739 - $1.32 Million
-8,428 Reduced 65.56%
4,428 $507,000
Q1 2023

May 15, 2023

SELL
$117.53 - $155.99 $658,873 - $874,479
-5,606 Reduced 30.37%
12,856 $1.77 Million
Q4 2022

Feb 10, 2023

BUY
$100.86 - $132.13 $666,482 - $873,115
6,608 Added 55.74%
18,462 $2.39 Million
Q3 2022

Nov 09, 2022

BUY
$75.71 - $119.24 $897,466 - $1.41 Million
11,854 New
11,854 $1.31 Million
Q2 2022

Aug 02, 2022

SELL
$62.69 - $88.44 $201,172 - $283,803
-3,209 Closed
0 $0
Q1 2022

May 05, 2022

BUY
$63.15 - $90.42 $202,648 - $290,157
3,209 New
3,209 $251,000
Q2 2021

Aug 10, 2021

SELL
$69.38 - $86.75 $1.29 Million - $1.62 Million
-18,621 Closed
0 $0
Q1 2021

May 11, 2021

BUY
$72.25 - $168.95 $1.35 Million - $3.15 Million
18,621 New
18,621 $1.39 Million
Q4 2020

Feb 12, 2021

SELL
$125.56 - $178.74 $373,164 - $531,215
-2,972 Closed
0 $0
Q3 2020

Nov 06, 2020

BUY
$127.12 - $172.34 $377,800 - $512,194
2,972 New
2,972 $417,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $10.9B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Aigen Investment Management, LP Portfolio

Follow Aigen Investment Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Aigen Investment Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Aigen Investment Management, LP with notifications on news.